|
시장보고서
상품코드
2077201
레미케이드 바이오시밀러 시장 : 제품 유형별, 최종사용자별, 적응증별, 지역별Remicade Biosimilars Market, By Product Type, By End User, By Indication, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
레미케이드 바이오시밀러 시장은 2026년에 43억 2,000만 달러 규모가 될 것으로 추정되며, 2033년까지 106억 1,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 13.7%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 43억 2,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 13.70% | 2033년 시장 규모 예측: | 106억 1,000만 달러 |
전 세계 레미케이드 바이오시밀러 시장에는 인플릭시맙, 아달리무맙, 에타넬셉트 및 이와 유사한 제품 유형이 포함됩니다. 이 제품들은 병원, 전문 클리닉, 소매 약국 등에서 사용되며, 다양한 최종사용자에게 채택되고 있습니다. 조직이 성과, 효율성, 비용 대비 효과를 점점 더 중시함에 따라, 이러한 부문에서의 채용은 꾸준히 확대되고 있습니다.
시장 역학:
주요 최종사용자 부문의 수요 증가, 효율성과 신뢰성 향상의 필요성, 그리고 지속적인 제품 혁신이 전 세계 레미케이드 바이오시밀러 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 병원과 전문 클리닉에서의 채용 확대가 이러한 추세를 더욱 강화하고 있습니다.
예를 들어, 시장에 진출한 각 기업은 병원에서의 사용 사례에 맞춰 설계된 첨단 솔루션을 도입하고 있습니다. 또한, 지속적인 기술 발전과 전략적 투자를 통해 예측 기간 동안 시장에 진출한 기업들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 레미케이드 바이오시밀러 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 레미케이드 바이오시밀러 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 레미케이드 바이오시밀러 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 레미케이드 바이오시밀러 시장 : 제품 유형별, 2026-2033년
제5장 레미케이드 바이오시밀러 시장 : 최종사용자별, 2026-2033년
제6장 레미케이드 바이오시밀러 시장 : 적응증별, 2026-2033년
제7장 레미케이드 바이오시밀러 시장 : 지역별, 2026-2033년
제1장 경쟁 구도
제2장 섹션
KSM 26.07.07Remicade Biosimilars Market is estimated to be valued at USD 4.32 billion in 2026 and is expected to reach USD 10.61 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.32 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.70% | 2033 Value Projection: | USD 10.61 billion |
The global remicade biosimilars market includes offerings that span Infliximab, Adalimumab, and Etanercept, and similar product type categories. These are applied across Hospitals, Specialty Clinics, and Retail Pharmacies and adopted by diverse end users. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from major end-use sectors, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global remicade biosimilars market. Broader adoption across Hospitals, and Specialty Clinics is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for Hospitals use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global remicade biosimilars market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Samsung Bioepis, Celltrion, Inc., Sandoz (a Novartis division), Biocon Ltd., Amgen Inc., Mylan N.V., Dr. Reddys Laboratories, Zydus Cadila, Intas Pharmaceuticals, Lupin Ltd., and Teva Pharmaceuticals, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global remicade biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global remicade biosimilars market.
Detailed Segmentation:
- Global Remicade Biosimilars Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
- Infliximab
- Adalimumab
- Etanercept
- Others
- Global Remicade Biosimilars Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Retail Pharmacies
- Others
- Global Remicade Biosimilars Market, By Indication (Revenue, USD Bn, 2021 - 2033)
- Rheumatoid Arthritis
- Crohns Disease
- Psoriasis
- Ulcerative Colitis
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Samsung Bioepis
- Celltrion, Inc.
- Sandoz (a Novartis division)
- Biocon Ltd.
- Amgen Inc.
- Mylan N.V.
- Dr. Reddys Laboratories
- Zydus Cadila
- Intas Pharmaceuticals
- Lupin Ltd.
- Teva Pharmaceuticals
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By End User
- Market Snapshot, By Indication
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Remicade Biosimilars Market By Product Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Infliximab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adalimumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Etanercept
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Remicade Biosimilars Market By End User, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Remicade Biosimilars Market By Indication, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Crohn's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Remicade Biosimilars Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Celltrion, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biocon Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dr. Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lupin Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
